[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632538":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":38,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":76,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sirolimus-coated DCB group","EXPERIMENTAL","Treatment of sirolimus-coated DCB",[13],"Device: Sirolimus-coated DCB",{"label":15,"type":16,"description":17,"interventionNames":18},"Paclitaxel-coated DCB","ACTIVE_COMPARATOR","Treatment of paclitaxel-coated DCB",[19],"Device: Paclitaxel-coated DCB",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DEVICE","Sirolimus-coated DCB",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Jie Zhao, MD, PhD","Chinese Academy of Medical Sciences, Fuwai Hospital","PRINCIPAL_INVESTIGATOR",[34],{"name":30,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","+8613911036089","fwzhaojie@126.com",[39],{"facility":40,"status":25,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Fuwai hospital, CAMS&PUMC","Beijing","Beijing Municipality","100037","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":54,"role":35,"phone":36,"phoneExt":25,"email":37},"Jie Zhao",{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100632538","sirolimus-coated-vs-paclitaxel-coated-dcbs-in-acs-treatment-100632538",false,"NCT07514988","Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment","Comparison Study of Sirolimus-Coated Versus Paclitaxel-Coated Coronary Drug-Coated Balloons in the Treatment of Acute Coronary Syndrome","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be enrolled:\n\n1. Age between 18 and 80 years old, both genders eligible;\n2. Coronary angiography showing non-complex lesions with acute coronary syndrome (non-ST-elevation myocardial infarction and unstable angina) deemed suitable for drug-coated balloon treatment by the investigator;\n3. Visually estimated lesion length ≤28mm, visually estimated vessel diameter ≥2.5mm and ≤3.0mm;\n4. Successful lesion pre-dilation (must simultaneously meet all 3 criteria: no Type C or greater dissection; TIMI flow grade 3; visually estimated residual stenosis ≤30%);\n5. Able to understand the study purpose, willing to complete follow-up visits, and voluntarily provide informed consent.\n\nExclusion Criteria:\n\nSubjects will be excluded if they meet any of the following criteria:\n\n1. Total occlusion (TIMI 0 flow) lesion;\n2. In-stent restenosis lesion;\n3. Concurrent left main disease or severe three-vessel disease requiring coronary artery bypass grafting;\n4. Target lesion with severe calcification or tortuosity that cannot be crossed by guidewire;\n5. Coronary artery bypass graft stenosis;\n6. Confirmed ST-elevation myocardial infarction;\n7. Cardiogenic shock or requiring mechanical respiratory and circulatory support;\n8. Hemodynamically unstable tachyarrhythmia or bradyarrhythmia;\n9. Severe renal insufficiency or undergoing hemodialysis;\n10. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media, paclitaxel, sirolimus and\u002For other analogues;\n11. Systemic lupus erythematosus or other systemic autoimmune diseases;\n12. History of stroke within 6 months prior to enrollment;\n13. Scheduled elective surgery within 6 months after enrollment requiring discontinuation of anticoagulant or antiplatelet medications;\n14. Currently participating in other drug or interventional medical device clinical studies;\n15. Other conditions deemed unsuitable for enrollment by the investigator.","ALL","18 Years","80 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"NA","This study aims to investigate and compare the local inflammatory responses and plaque healing characteristics between sirolimus-coated and paclitaxel-coated coronary drug-coated balloons in patients with acute coronary syndrome.",[75],"Acute Coronary Syndromes (ACS)","NOT_YET_RECRUITING","2026-03-31",{"date":79,"type":80},"2026-04-07","ACTUAL",{"date":82,"type":69},"2026-05-01",{"date":84,"type":69},"2028-07-01",{"name":5,"class":6},1]